Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis

Delivering anti-inflammatory peptides directly to the colon represents an ideal strategy for treating inflammatory bowel disease while minimizing systemic side effects. This study by Xiao, Xu, Viennois, and colleagues developed hyaluronic acid-functionalized nanoparticles to deliver the tripeptide KPV orally to the site of intestinal inflammation.

The researchers engineered nanoparticles coated with hyaluronic acid to protect KPV during transit through the gastrointestinal tract and enable targeted release at inflamed colonic tissue. They evaluated the nanoparticle system's ability to alleviate ulcerative colitis in established animal models, measuring inflammatory markers and tissue damage.

The results demonstrated that orally delivered KPV nanoparticles efficiently alleviate ulcerative colitis, with the targeted delivery system successfully concentrating the anti-inflammatory peptide at the site of disease. This approach achieved therapeutic effects through a convenient oral route rather than requiring injection.

For patients with inflammatory bowel disease, this research establishes a viable oral therapeutic approach that combines KPV's natural anti-inflammatory properties with advanced drug delivery technology. The ability to take an effective peptide therapy by mouth rather than injection could significantly improve treatment adherence and patient quality of life.